Granted Patent
B2
US 8,754,202 · App. 13/169,549 · Granted Jun 17, 2014
RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis
Inventors:
Jon E. Chatterton (Forth Worth, TX); Abbot F. Clark (Arlington, TX); David P. Bingaman (Weatherford, TX); Martin B. Wax (Westlake, TX); Adrian M. Timmers (Forth Worth, TX)
Assignee:
Alcon Research, Ltd
View Patent ↗
Loading inventors, assignments & file history…
Abstract
RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
Claims (1)
1. A small interfering RNA (siRNA) molecule comprising a sense strand and an antisense strand, wherein the sense strand is a 19 nucleotide RNA sequence corresponding to SEQ ID NO: 14.
Assignments (3)
CHANGE OF NAME
Recorded Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0710 →
SECURITY INTEREST
Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035653/0635 →
Continuity (4)
Provisional Application
60953825
· Aug 3, 2007